Arcus Biosciences pegs Sept 30, 2026 cash and marketable securities at ~$694.0M

Arcus Biosciences, Inc.

Preliminary estimate of approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026.
Filing discloses no revenue, EPS, burn rate or cash runway figures; it is a cash-balance update only.
Estimate is unaudited and subject to completion of financial closing procedures; Ernst & Young has not audited, reviewed or compiled the figure.
Company cautions the balance may vary from the actual September 30, 2026 position and is not indicative of future periods.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.